Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
LFCR Stock Chart & Stats
$7.71
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.71
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$4.76 - $8.85
Previous CloseN/A
Volume140.23K
Average Volume (3M)204.26K
Market Cap
$291.11M
Enterprise Value$418.81M
Total Cash (Recent Filing)$18.86M
Total Debt (Recent Filing)$137.53M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Apr 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,466,350
10 Day Avg. Volume178,832
30 Day Avg. Volume204,257
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)4.93
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-59.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Wins And PipelineSigning multiple development programs and a commercial site transfer contract with a large pharma customer expanded the near-term revenue pipeline and adds a potential high-revenue product.
Industry Demand TailwindsAccelerating manufacturing regionalization and increased commercial site transfer activity created sustained demand tailwinds for U.S.-based CDMO services, benefiting the company's growth outlook.
Revenue GrowthTop-line expansion in the CDMO business was driven by higher sales volumes and improved pricing, supporting expectations for stronger revenue momentum.
Bears Say
Balance Sheet And ValuationSignificant balance sheet leverage and current valuation metrics prompted an analyst to maintain a market-perform rating, indicating limited upside until deleveraging occurs.
Financial Data UncertaintyKey reported figures were presented as approximations from third-party sources, introducing uncertainty around the accuracy of financial results and guidance.
Profitability MissReported earnings per share fell short of analyst estimates, signaling near-term profitability pressure and potential downward revisions to earnings forecasts.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $4.76 and its highest was $8.85 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $291.11M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Apr 07, 2026 which is in 84 days.
How were Lifecore Biomedical’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Overvalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,466,350 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 30.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.55%
Trailing 12-Months
Company Description
Lifecore Biomedical
Lifecore Biomedical (LFCR) is a leading medical technology company specializing in the development and manufacturing of advanced biomaterials and medical devices. The company operates primarily within the biotechnology and medical device sectors, focusing on regenerative medicine, particularly in the areas of orthopedic and dental applications. Lifecore's core products include hyaluronic acid-based injectable solutions, which are used in various surgical applications, as well as custom contract manufacturing services for other medical device companies.
LFCR Company Deck
LFCR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic advancements in customer partnerships, pipeline progress, and operational efficiencies, suggesting a focus on long-term growth. However, the quarter experienced a decline in revenue and a net loss, influenced by specific non-recurring adjustments and increased SG&A expenses. Overall, the sentiment reflects cautious optimism, balancing growth initiatives with current financial challenges.View all LFCR earnings summariesLFCR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.32% Insiders
6.18% Mutual Funds
45.20% Other Institutional Investors
24.68% Public Companies and
Individual Investors